" class="no-js "lang="en-US"> Merck - Medtech Alert
Friday, March 29, 2024
Merck | Pharmtech Focus

Merck

About Merck

Merck

Merck is a leading global biopharmaceutical company that has been inventing for life for more than a century, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world – including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. This site is intended for residents of the United States and its territories. For more information, visit www.merck.com.

Related Story

Merck & XtalPi Collaboration Optimizes Drug Formulations with AI-Powered Techniques

April 14 2023

Science and technology company Merck and XtalPi, a pioneering pharmaceutical technology company powered by artificial […]

Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merck

March 28 2023

Ratio Therapeutics, a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class […]

Aqilion announces Pre-clinical Licensing and Strategic Research Collaboration Agreement with Merck

February 16 2023

Aqilion today announced an exclusive license and strategic research collaboration with Merck to discover, develop […]

Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO Chews for Dogs

January 26 2023

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, […]

Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer

December 22 2022

Merck, known as MSD outside of the United States and Canada, and Kelun-Biotech, a clinical-stage […]

Curve Therapeutics Announces Collaboration with MSD for Next Generation Drug Discovery Platform

February 16 2022

Curve Therapeutics (Curve), a private biotechnology company pioneering a potentially game-changing, functional drug discovery platform, today […]

Merck KGaA, Darmstadt, Germany, Enters into Option Agreement with Quris on its BioAI Platform for Clinical Safety Prediction

February 9 2022

Quris, an artificial intelligence (AI) innovator disrupting the pharmaceutical arena, today announced it has signed […]

Merck and Ridgeback’s Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First Authorization in the World

November 4 2021

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics […]